Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Analyst Optimism | Price targets range from $15 to $23, with a consensus recommendation leaning strongly toward Buy, reflecting confidence in Third Harmonic Bio's potential |
Financial Strength | With $255.3 million in cash, Third Harmonic Bio is well-positioned to fund operations through 2026, supporting clinical development without immediate funding concerns |
Market Potential | Analysts estimate peak US sales for chronic spontaneous urticaria at $2.7 billion, highlighting the significant commercial opportunity for THB335 |
Pioneering Treatment | Third Harmonic Bio's THB335, an oral wild-type KIT inhibitor, shows promise in addressing mast-cell driven diseases, with potential applications beyond initial targets |
Metrics to compare | THRD | Peers Peers - average of corresponding metrics from companies closely matching THRD: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTHRDPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.4x | |
Upside (Analyst Target) | 0.0% | 0.0% | 44.9% | |
Fair Value Upside | Unlock | 0.0% | 6.3% | Unlock |